Skip to main content

Advertisement

Table 2 CTC KIN and association with PFS, OS, and progression at 3-month radiological examination

From: Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients

  CTCBL(baseline)   CTC1C(after 1st cycle) PFS (months) OS (months) Progression
     Median [95% CI] Median [95% CI] Numbers (percentage)
Favorable Negative (CTC BL -) Negative (CTC 1C -) 8.7 [6.6–11.5] 30.6 [27.4–na] 20/75 (27%)
Positive (CTC BL +) Negative (CTC 1C -) 8.0 [5.5–12.1] 16.7 [13.6–na] 11/32 (34%)
Unfavorable Positive (CTC BL +) Positive (CTC 1C +) 4.3 [3.6–6.1] 7.7 [6.1–13.1] 21/41 (51%)
Negative (CTC BL -) Positive (CTC 1C +) 3.7 [2.5–na] 14.0 [5.7–na] 3/6 (50%)
  1. na = not available.